Disease landscape

Sickle Cell Disease clinical trials

Get alerts when Sickle Cell Disease trials change

261 active trials 159 recruiting 23 Phase 3 133 sponsors 83 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-08-28

What changed in the last 30 days showing 58 of 83 changes on 19 trials

2026-08-26
Withdrawn before enrolling
Trial withdrawn: not a clinical trial
Enrollment reduced: 50 → 0 participants
NCT06562439 Testing the Sickle Cell Caregiver Collaboration for Child Development (SCCCD) Intervention · Washington University School of Medicine
2026-08-07
Primary completion pushed: 2026-03-31 → 2026-06-30
Phase changed: Phase 1/2 → Phase 2
Trial completed
Enrollment increased: 9 → 13 participants
NCT06144749 A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide… · Hillhurst Biopharmaceuticals, Inc. · Phase 2
2026-08-22
Primary completion pushed: 2027-11-25 → 2028-11-25
Recruitment opened
Completion pushed: 2027-11-25 → 2028-11-25
NCT06761560 Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to… · Yves Pastore · Phase 2/3
2026-08-12
Primary completion pushed: 2028-04 → 2029-04
Completion pushed: 2028-09 → 2029-10
NCT06743113 Hypoxic Red Blood Cells in Sickle Cell Anemia · Hemanext
2026-08-25
Primary completion pushed: 2025-12 → 2028-11
Completion pushed: 2025-12 → 2028-11
NCT02306993 Sickle Cell Hemoglobinopathies and Bone Health · UConn Health
2026-08-22
Primary completion pushed: 2025-12 → 2026-07-23
Trial status changed: Unknown → Completed
Completion pushed: 2025-12 → 2026-07-23
NCT06264700 Applying Directly Observed Therapy to Hydroxyurea to Realize Effectiveness · Nationwide Children's Hospital
2026-08-22
Primary completion pushed: 2027-12-31 → 2028-12-31
Completion pushed: 2028-12-31 → 2029-06-30
NCT07530965 Omega-3-Fatty Acids in Children With Sickle Cell Disease · University of Alabama at Birmingham
2026-08-20
Primary completion pushed: 2026-03-31 → 2027-03-31
Enrollment closed, study ongoing
Completion pushed: 2026-03-31 → 2027-03-31
NCT04406818 Metabolic and Hemodynamic Reserve in Pediatric SCA · Washington University School of Medicine
2026-08-14
Primary completion pushed: 2026-08-01 → 2028-08-01
Completion pushed: 2027-08-01 → 2028-08-01
NCT03653338 T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD)… · Paul Szabolcs · Phase 1/2
2026-07-30
Primary completion pushed: 2026-07 → 2028-01
Completion pushed: 2026-07 → 2028-01
NCT02447874 Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease · Emory University · Phase 1/2
2026-08-13
Primary completion pushed: 2026-04-02 → 2030-06-28
Sponsor changed: Indiana University → University of Cincinnati
Enrollment reopened
Enrollment increased: 10 → 120 participants
Completion pushed: 2027-04-02 → 2031-06-28
NCT06725550 Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0 · University of Cincinnati
2026-08-01
Primary completion pushed: 2025-02-01 → 2025-09-16
Enrollment reduced: 40 → 36 participants
Trial completed
Completion pushed: 2025-02-01 → 2025-09-16
NCT04688411 An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell… · Ann & Robert H Lurie Children's Hospital of Chicago
2026-08-13
Primary endpoint(s) modified
Enrollment increased: 6 → 59 participants
Trial sites expanded: 4 → 23 locations
NCT05777993 A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an… · Agios Pharmaceuticals, Inc. · Phase 4
2026-08-19
Enrollment reduced: 20 → 15 participants
Trial completed
Primary completion moved earlier: 2026-12-31 → 2026-03-11
Completion moved earlier: 2027-12-31 → 2026-03-31
NCT04925492 PET Imaging of Vaso-Occlusive Crisis (VOC) in SCD · Enrico Novelli · Phase 1
2026-08-01
Enrollment reduced: 300 → 59 participants
Primary completion moved earlier: 2031-11 → 2026-01-30
Completion moved earlier: 2032-05 → 2027-01-30
NCT06511453 Acupressure in Patients With Sickle Cell Disease · Indiana University
2026-08-01
Enrollment reduced: 120 → 10 participants
Enrollment closed, study ongoing
Primary completion moved earlier: 2029-08-31 → 2026-04-02
Completion moved earlier: 2030-08-30 → 2027-04-02
NCT06725550 Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0 · University of Cincinnati
2026-08-08
Phase changed: Early Phase 1 → Phase 1/2
Completion pushed: 2028-04-30 → 2028-06-30
NCT07648043 Feasibility and Acceptability of Amani · Massachusetts General Hospital · Phase 1/2
2026-08-18
Recruitment opened
Primary completion pushed: 2028-11 → 2029-01
Trial sites expanded: 0 → 4 locations
NCT07282210 Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease… · Biossil Inc. · Phase 2
2026-08-05
Recruitment opened
Trial sites expanded: 0 → 3 locations
NCT07656415 A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With… · Agios Pharmaceuticals, Inc. · Phase 3
2026-08-28
Trial completed
Enrollment increased: 20 → 25 participants
NCT07402811 Mindfulness-Based Intervention for Pain and Sleep in Adolescents and Young Adults With… · University of Illinois at Chicago

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-08-07 NCT07753681 Domestication and Implementation of the PEN-Plus Clinical Model in the Zambian Health… Centre for Infectious Disease Research in Zambia new
2026-07-22 NCT07721155 Objective Neurocognitive Assessment of Young Children With Sickle Cell Disease by… Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) new
2026-07-06 NCT07682662 Low Dose Bolus Ketamine For Use In Sickle Cell Pain Crisis University of Mississippi Medical Center new Phase 4

Active trials by phase

Early Phase 1
5
Phase 1
17
Phase 1/2
29
Phase 2
36
Phase 2/3
3
Phase 3
20
Phase 4
10
Not charted: 141 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 261

NCT IDTitleSponsorStatusUpdated
Phase 4
NCT04657822 Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior… Novartis Pharmaceuticals Recruiting 2026-06-08
NCT06665997 Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With… University of Pennsylvania Recruiting 2026-05-28
NCT06526117 Stroke Prevention in Nigeria 2 Trial Vanderbilt University Medical Center Recruiting 2026-03-05
NCT06979492 Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease Emory University Recruiting 2026-02-18
NCT07177300 Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations… Children's Hospital Medical Center, Cincinnati Recruiting 2025-09-16
NCT05777993 A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an… Agios Pharmaceuticals, Inc. Enrolling by Invitation 2026-08-12
NCT07682662 Low Dose Bolus Ketamine For Use In Sickle Cell Pain Crisis University of Mississippi Medical Center Not Yet Recruiting 2026-07-06
NCT05730205 Effects of the Contraceptive Implant in Women With Sickle Cell Disease University of Pennsylvania Active, Not Recruiting 2026-06-12
NCT07488520 Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle… Swiss Tropical & Public Health Institute Not Yet Recruiting 2026-03-23
NCT06579703 Ketorolac for Acute Vaso-Occlusive Crisis in Pediatric Sickle Cell Disease Children's Blood and Cancer Center at Dell Children's Medical Center Not Yet Recruiting 2024-08-30
Phase 3
NCT05285917 Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa Brown University Recruiting 2026-08-20
NCT06439082 A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With… Novartis Pharmaceuticals Recruiting 2026-08-19
NCT06609226 A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle… Novo Nordisk A/S Recruiting 2026-08-13
NCT06612268 A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease Novo Nordisk A/S Recruiting 2026-08-13
NCT07656415 A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With… Agios Pharmaceuticals, Inc. Recruiting 2026-08-04
NCT06975865 The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With… Sanofi Recruiting 2026-07-29
NCT07274254 Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease Nantes University Hospital Recruiting 2026-07-13
NCT06818266 Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With… Assistance Publique - Hôpitaux de Paris Recruiting 2026-06-24
NCT07247188 Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and… Sanofi Recruiting 2026-04-15
NCT05477563 Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With… Vertex Pharmaceuticals Incorporated Recruiting 2026-03-23
NCT05392894 RElated Haplo-DonoR Haematopoietic stEm Cell Transplantation for Adults With Severe… King's College Hospital NHS Trust Recruiting 2023-05-10
NCT04084080 Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE) University of Pittsburgh Active, Not Recruiting 2026-08-25
NCT03814746 Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell… Novartis Pharmaceuticals Active, Not Recruiting 2026-08-13
NCT04208529 A Long-term Follow-up Study in Participants Who Received CTX001 Vertex Pharmaceuticals Incorporated Enrolling by Invitation 2026-08-11
NCT05329649 Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle… Vertex Pharmaceuticals Incorporated Active, Not Recruiting 2026-07-01
See all 261 active Sickle Cell Disease trials with filters →

Top sponsors by active trials in this area

St. Jude Children's Research Hospital (16) · National Heart, Lung, and Blood Institute (NHLBI) (14) · Assistance Publique - Hôpitaux de Paris (13) · Children's Hospital Medical Center, Cincinnati (12) · Emory University (6) · Novartis Pharmaceuticals (5) · Vanderbilt University Medical Center (5) · Washington University School of Medicine (5) · Agios Pharmaceuticals, Inc. (4) · Centre Hospitalier Universitaire de la Guadeloupe (4)

Get alerts when Sickle Cell Disease trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free